Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington's disease

Abstract

Objective: In addition to neurological impairment, weight loss is a prominent characteristic of Huntington's disease (HD). Neuropathologically, the disease affects the caudate nucleus and the cerebral cortex, and also the hypothalamus. The recently discovered orexigenic hormone of gastric origin, ghrelin and the adipocyte hormone leptin, are two peripherally produced hormones exerting opposite effects on specific populations of hypothalamic neurons that play a key role in regulating energy intake and energy output. The aim of this study was to investigate the possible involvement of cerebrospinal fluid (CSF) and circulating ghrelin and leptin in the regulation of energy balance in patients with HD. Methods: Twenty healthy normal-weight subjects undergoing orthopedic surgery and fifteen patients with genetically verified HD, were enrolled in this study. The unified Huntington's disease rating scale (UHDRS) was used to assess clinical course of the disease. Blood samples for hormonal measurements were obtained by venipuncture and in-parallel CSF samples for leptin/ghrelin determination were obtained by lumbar puncture. Results: Patients with HD had increased concentrations of ghrelin in plasma compared with healthy subjects (4523.7 ± 563.9 vs 2781.1 ± 306.2 pg/ml, P < 0.01). On the other hand, patients with HD had decreased concentrations of leptin in plasma compared with healthy subjects (4.8±1.6 vs 10.9±2.4ng/ml, P < 0.01). The concentrations of CSF ghrelin and CSF leptin were equivalent to values in healthy subjects. No correlation was found between disease duration - and other clinical features of HD - and plasma or CSF leptin/ghrelin levels. In patients with HD, baseline levels of GH, IGF-I, insulin and glucose did not differ from those in healthy subjects. Conclusion: High circulating ghrelin and low leptin levels in patients with HD suggest a state of negative energy balance. Early nutritional support of patients with HD is advocated since patients with HD and higher body mass index at presentation have slower progression of the disease. © 2004 Society of the European Journal of Endocrinology.